ASH 2016 – Saturday, December 3

Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting

Oral Presentations

7:45 a.m.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Co-Authors: Karam Al-Issa, MD, Ahmad Zarzour, MD, Tomas Radivoyevitch, PhD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Aaron T. Gerds, MD, MS, Sudipto Mukherjee, M.D., Ph.D., M.P.H., Vera Adema, PhD, Michael J. Clemente, M.S., Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Anjali S. Advani, MD, Bartlomiej P Przychodzen, MSc, Hetty E. Carraway, MD, MBA, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS, Aziz Nazha, MD

Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best

Manchester Grand Hyatt San Diego, Grand Hall C

10:15 a.m.

Co-Authors: Andrea Kuendgen, Heinz Tuechler, Meritxell Nomdedeu, Detlef Haase, Guillermo Garcia-Manero, Rami S. Komrokji, Francesc Sole, Mikkael A.Sekeres, Matteo Giovanni Della Porta, Alan F List, Mario Cazzola, Amy E. DeZern, Gail J. Roboz, David P. Steensma, Arjan A van de Loosdrecht, Richard F. Schlenk, Xavier Calvo, Sabine Blum, Arturo Pereira, PeterValent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carmen Pedro, Michael Lübbert, Maria Teresa Cedena, Julie Schanz, Sigrid Machherndl-Spandl, Maria Lopez-Pavia, Ana Africa Martin, Claudia D Baldus,Montserrat Martínez de Sola, Reinhard Stauder, Brayan Merchan, Claudia Mende, Maria Teresa Voso, María Teresa Ardanaz, Christina Ganster, Katayoon Shirneshan, Francesc Cobo, Thomas Schroeder, Jordi Esteve, Rainer Haas, Nomdedeu Benet, Peter L. Greenberg, Ulrich Germing, Guillermo Sanz

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome – a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Manchester Grand Hyatt San Diego, Grand Hall C

12:45 p.m.

Co-Authors: Robert Molokie, Donald Lavelle, Michel Gowhari, Michael Pacini, Lani Krauz, Johara Hassan, Vinzon Ibanez, Maria A. Ruiz, Daisy Pacelli, Sherry Fada, Mitch Phelps, Lewis Hsu, Victor Gordeuk, Joseph DeSimone, Yogen Saunthararajah

Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine as Non-Cytotoxic Epigenetic Disease-Modification for Sickle Cell Disease
San Diego Convention Center, Room 28 A-D

1:15 p.m.

Co-Authors: Alok A. Khorana, MD, Jeffrey S Berger, MD, Philip S Wells, MD, Roger Seheult, MD, Veronica Ashton, MPH, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Dominique Lejeune, MA, Jeff Schein, DrPH, MPH, Peter Wildgoose, PhD, Patrick Lefebvre, MA, Scott Kaatz, DO, MSc
Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

San Diego Convention Center, Room 3

4:00 p.m.

Co-Authors: Harry Erba, Moshe Y. Levy, Sumithira Vasu, Anthony S. Stein, Amir T. Fathi, Michael B. Maris, Anjali S. Advani, Stefan Faderl, Brent L. Wood, Scott Smith, Roland B. Walter, Jay Yang, William B. Donnellan, Eric J. Feldman, Jenna L. Voellinger, Farhad Ravandi

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Marriott Marquis San Diego Marina, San Diego Ballroom AB

4:45 p.m.

Co-Authors: Elias Jabbour MD, Nicholas J. Short MD, Xuelin Huang PhD, Abhishek Maiti MD, Tapan Kadia MD, Naval Daver MD, Gautam Borthakur MD, Courtney DiNardo MD, Naveen Pemmaraju MD, Koji Sasaki, Zeev Estrov MD, Srdan Verstovsek MD PhD, Farhad Ravandi MD, Yesid Alvarado MD, Mikkael A. Sekeres, MD, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J Roboz MD, Darla Miller BS, Sherry Pierce BS, Hagop Kantarjian MD, Guillermo Garcia-Manero MD

A Randomized Phase II Study of Low-Dose Decitabine versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes

Manchester Grand Hyatt San Diego, Grand Hall C

5:15 p.m.

Co-Authors: Mohamed Sorror, MD, MSc; Barry Storer, PhD; Mahmoud ElSawy, MD; Amir Fathi, MD; Andrew Brunner, MD; Aaron T Gerds, MD,MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD; Bruno Medeiros, MD; Eunice Wang, MD; Pankit Vachhani, MD; Paul Shami, MD; Esteban Pena, MD; Shylo Wardyn, MS; Jennifer Whitten, MPH; Rachelle Moore, BS ; Pamela Becker, MD, PhD; Jeannine McCune, PharmD; Stephanie Lee, MD; Brenda Sandmaier, MD; Frederic Appelbaum, MD; Elihu Estey, MD

Intensive versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) using Two Different Novel Prognostic Models

Marriott Marquis San Diego Marina, San Diego Ballroom AB

5:15 p.m.

Co-Authors: Mohamed Samour, MBBS, Caner Saygin, MD, Rashid Abdallah, RN, Suman Kundu, MS, MBA and Keith R. McCrae, MD

Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study

San Diego Convention Center, Room 33

5:15 p.m.

Co-Authors: Katharine Batt, MD, MSc, Michael Recht, MD, PhD, Michael Wang, MD, Doris V. Quon, MD, PhD, Lisa Boggio, MD, Craig M. Kessler, MD, Tyler W. Buckner, MD, MSc, Anne T. Neff, MD, Neeraj N Iyer, PhD, David L Cooper, MD, MBA and Christine L Kempton, MD, MSc

Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

San Diego Convention Center, Room 7AB

Poster Viewing

Hall G

Advertising Policy

Saturday, December 3
9:00 a.m. – 7:30 p.m. Poster Session I – Viewing
5:30 p.m. – 7:30 p.m. Poster Session I – Presentations

Prognostic Factors for Late Mortality among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT)
Co-Authors: Sagar S. Patel, MD, Lisa Rybicki, MS, Donna Abounader, BBA, CCRP, Brian Bolwell, MD, Robert Dean, MD, Hien Liu, MD, Aaron Gerds, MD, Rabi Hanna, MD, Brian Hill, MD, PhD, Deepa Jagadeesh, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Navneet S. Majhail MD, MS, Betty K. Hamilton, MD

IL-27 Enhances Inducible Foxp3+ Treg Function to Prevent Acute Graft-versus-Host Disease Lethality
Co-Authors: Betty K. Hamilton, Jeongsu Do, and Booki Min

Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease
Co-Authors: Alicia M Stallings, BA, Navneet S Majhail, MD, MS, Amy S Nowacki, PhD, Grace I Onimoe, MD, Rabi Hanna, MD, Charles Quinn, MD,MS, Lewis Hsu, MD, Jillian Wen, B.S., Connie M Piccone, MD

Clinician Practices and Perspectives of HCT as a Treatment Option for Sickle Cell Disease
Co-Authors: Alicia M Stallings, BA, Navneet S Majhail, MD, MS, Amy S Nowacki, PhD, Grace I Onimoe, MD, Rabi Hanna, MD, Connie M Piccone, MD

Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome
Co-Authors: Kasiani C. Myers, MD, Adam Nelson, MBBS, Brian, Sheehan, Maggie Malsch, Gwendolyn Towers, Audrey Anna Bolyard, RN, BS, Joan Moore, Sara Loveless, Leann Mount, Stella M. Davies, MBBS, PhD, Sioban, Keel, MD, Rabi Hanna, MD , Mark Fleming, David C. Dale, MD and Akiko Shimamura, MD, PhD

Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity
Co-Authors: Daniel J Landsburg, MD, Nishitha Reddy, MD, MSCI, MBBS, Christina Howlett, PharmD, BCOP, Tatyana Feldman, MD, Anthony R. Mato, MD MSCE, Jason B Kaplan, MD, Amir Behdad, MD, Adam M. Petrich, MD, Joseph Maly, MD, Kristie Blum, MD, Julio C. Chavez, MD, Shaoying Li, MD, L. Jeffrey Medeiros, MD, Marissa K. Falkiewicz, Brian T. Hill, MD, PhD, Arun Singavi, MD, Timothy S. Fenske, MD, James Gerson, MD, Stefan Klaus Barta, MD, MRCP, MS, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Cristiana A Costa, DO, Frederick Lansigan, MD, Oscar Calzada, BS, Jonathon B. Cohen, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Xavier Rivera, Daniel Oscar Persky, MD, David Peace, MD and Ryan D Cassaday, MD

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)
Co-Authors: Brian T. Hill, MD, PhD, Kwang Woo Ahn, PhD, Zhenhuan Hu, MPH, Matt Kalaycio, MD, Richard T. Maziarz, MD, Jorge E. Cortes, MD, Edwin Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD and Wael Saber, MD, MS

Impact of Human Leukocyte Antigen (HLA) Alleles on Outcomes of Allogeneic Transplantation (Allo-HCT) for B-Cell Non-Hodgkin Lymphomas (B-NHL); A CIBMTR Analysis
Co-Authors: Basem M William, MD, Tao Wang, PhD, Michael D Haagenson, MS, Marcos J de Lima, MD, Marcelo Anibal Fernandez-Vina, PhD, Spellman Stephen, M.B.S., Stephanie J. Lee, MD, Brian T. Hill, MD, Ph.D

Higher Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) Is Associated with Poor Psychosocial Health Pre-Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients
Co-Authors: Pradnya D Patil, MD, Lisa Rybicki, MS, Donna Abounader, BBA, CCRP, Hien K. Liu, MD, Brian T. Hill, MD, PhD, Robert Dean, MD, Betty K. Hamilton, MD, Aaron T. Gerds, MD, MS, Brad Pohlman, MD, Ronald Sobecks, MD, Brian J. Bolwell, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD, Deepa Jagadeesh, MD, MPH

Pre-transplant Psychosocial Assessment and Outcomes of Allogeneic Hematopoietic Cell Transplantation In Adults
Co-Authors: Sanghee Hong, Lisa Rybicki, Donna Abounader, Jane Dabney, Robert Dean, Aaron T. Gerds, Deepa Jagadeesh, Christine Lawrence, Betty K Hamilton, Brian Hill, Hien Liu, Matt Kalaycio, Linda McLellan, Brad Pohlman, Ronald Sobecks, Brian Bolwell, Navneet S Majhail

Major Bleeding Events Among Cancer and Non-Cancer Patients Taking Rivaroxaban for Venous Thromboembolism Treatment in a Department of Defense Health System Cohort
Co-Authors: Alok A. Khorana, MD, Frank Peacock, MD, Sally G Tamayo, MD, Zhong Yuan, MD, Nicholas Sicignano, MPH, Kathleen Hopf, MPH and Manesh Patel, MD

Decrease in Awareness of Hematologic Malignancies in the United States: Temporal Analysis of Google Trends Search Data from 2004 to 2015
Co-Authors: Adeel M. Khan, MD, MPH, Alok A. Khorana, MD

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study
Co-Authors: Davendra P. S. Sohal, MD, MPH, Nicole M. Kuderer, M.D., Frances A. Shepherd, MD, FRCPC, Ingrid Pabinger, Prof, Giancarlo Agnelli, MD, Howard A. Liebman, MA, MD, Eric Vicaut, MD, Guy Meyer, MD, Gary H. Lyman, MD, MPH, Alok A. Khorana, MD

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer
Co-Authors: Alok A. Khorana, MD, Keith R. McCrae, MD, Dejan Milentijevic, Jonathan Fortier, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH

Recombinant ß2-Glycoprotein I (ß2GPI) Produced Using a Novel Lentiviral Approach Functions at Least As Well As Plasma-Derived ß2GPI in Detection of Anti-ß2GPI Antibodies
Co-Authors: Mohamed Samour, MBBS, Shruti Chaturvedi, MBBS, Sergei Merkulov, Ph.D., Caner Saygin, MD, Heesun J Rogers, MD, PhD, Suman Kundu, MS, MBA and Keith R. McCrae, MD

Regulation of the Tumor Microenvironment By High Molecular Weight Kininogen
Co-Authors: Meenal Shukla, Ph.D., Venkaiah Betapudi, Ph.D., Ravi Kumar Alluri, Ph.D., Sergei Merkulov, Ph.D., James Hale, Ph.D., Justin Lathia, Ph.D. and Keith R. McCrae, MD

Post Traumatic Stress Disorder and Depression in Survivors of Thrombotic Thrombocytopenic Purpura
Co-Authors: Shruti Chaturvedi, MBBS, Olalekan O Oluwole, MBBS, MPH, Sydney Kodatsky, Spero Cataland, MD and Keith R. McCrae, MD

Von Willebrand Factor to Prevent Postpartum Hemorrhage
Co-Authors: Nicoletta Machin, MD, Margaret V. Ragni, MD, Andra H. James, MD, MPH, Craig D. Seaman, MD, Lynn M. Malec, MD, Craig M. Kessler, MD, Barbara Konkle, MD, Peter Kouides, MD, Anne T. Neff, MD, Claire S. Philipp, MD and Maria M. Brooks, PhD

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML)
Co-Authors: Anjali S. Advani, Brenda Cooper, Paul Elson, Sudipto Mukherjee, Jaime Fensterl, Aaron Gerds, Paolo Caimi, Ben Tomlinson, Ethsan Malek, Jane Little, Mary Lynn Rush, Samjhana Bogati, Eric Parsons, Donna Kane, Hetty Carraway, Aziz Nazha, Betty Hamilton, Ronald Sobecks, Barbara Bevier, Christopher Goebel, Cassie Zimmerman, Alek Nielsen, Cassandra Hirsch, Jaroslaw Maciejewski, Matt Kalaycio, Marcos deLima, James Jacobberger, Philip Woost, Mikkael A. Sekeres

A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312)
Co-Authors: Anjali S. Advani, MD, Anna Moseley, Michaela Liedtke, MD, Margaret O’Donnell, MD, Megan Othus, PhD, Martha P. Mims, MD PhD, Kristen O’Dwyer, MD and Harry P. Erba, MD, PhD

Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response
Co-Authors: Caner Saygin, MD; Nikolaos Papadantonakis, MD, PhD; Ryan Cassaday, MD; Michaela Liedtke, MD; Bhumika Patel, MD; Sean Hobson; Cassie Zimmerman, Jaime Fensterl, Ronald Sobecks, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, MPH; Aaron Gerds, MD, MS; Betty Hamilton, MD; Hetty Carraway, MD; Anjali S. Advani, MD

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia
Co-Authors: Mrinal M. Patnaik, MBBS, Vikas Gupta, MD, Jason Gotlib, MD, Hetty Carraway, MD, Martha Wadleigh, MD, Gary Schiller, MD, Moshe Talpaz, MD, Cecilia Arana-Yi, MD, Sangmin Lee, MD, James McCloskey, MD, Abdulraheem Yacoub, MD, Harris Ali, MD, Miakshi Taparia, MD, Janice Chen, PhD, Shay Shemesh, MA, Chris Brooks, PhD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD, PhD, Naveen Pemmaraju, MD

Aldehyde Dehydrogenase Activity in the Leukemic Stem Cell Compartment Uncovers Opposing Methylation Patterns of Leukemia Stem Cells in AML
Co-Authors: Lauren Suarez, Tingting Qin, PhD, Kristen Meldi, PhD, Manjusha Thakar, Sarah Sakoian, Gabriel Ghiaur, MD, PhD, Jonathan M. Gerber, MD, Hetty E. Carraway, Maria E Figueroa, MD and Steven D. Gore, MD

Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
Co-Authors: Bhumika Patel, MD, Caner Saygin, MD, Bartlomiej P Przychodzen, MSc, Teodora Kuzmanovic, BSc, Cassandra M. Hirsch, BSc, Michael J. Clemente, M.S., Swapna Thota, MD, Aziz Nazha, MD, Sekeres A Mikkael, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, and Hetty E. Carraway, MD, MBA

Rationale for Therapy Discontinuation in Patients With Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
Co-Authors: Aaron T. Gerds, MD, MS, Shaloo Gupta, MS, Gary Binder, MBA, Mikkael A. Sekeres, MD, MS,  Dr. Aziz Nazha, MD, Hetty E, Carraway, MD, MBA,  Stephanie Hawthorne, PhD, Kristen King-Concialdi, BS, Michael McGuire, PharmD

Evolving Risk of Myelodysplastic Syndromes among Adolescents and Young Adults Following Radiation Treatment for First Cancers in the United States, 1973 – 2014
Co-Authors: Remco Molenaar, MD, PhD, MPH; Tomas Radivoyevitch, PhD; Hetty Carraway, MD, MBA; Jaroslaw P. Maciejewski, MD, PhD, FACP; Mikkael A. Sekeres, MD, MS, and Sudipto Mukherjee, MD, PhD, MPH

Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Patients Treated in Randomized Clinical Trials
Co-Authors: Raffi Tchekmedyian, MD, Paul Elson, DSc, Aaron T Gerds, MS, MD, Navneet Majhail, MD, Hetty Carraway, MD, MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, and Sudipto Mukherjee, MD, PhD, MPH

Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy
Co-Authors: Sagar S. Patel, MD, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MS, MD, Navneet Majhail, MD, Hetty E. Carraway, MD, MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, and Sudipto Mukherjee, MD, PhD, MPH

BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes
Co-Authors: Nour Abuhadra, MD, Karam Al-Issa, MD, Aaron T. Gerds, MD, MS, Sudipto Mukherjee, M.D., Ph.D., M.P.H., Bhumika Patel, MD, Michael J. Clemente, M.S., Vera Adema, PhD, Cassandra M. Hirsch, BSc, Anjali S. Advani, MD, Mai Aly, Przychodzen P Bartlomiej, Hetty E. Carraway, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, M.D., M.S., Aziz Nazha, MD

Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival
Co-Authors: Megan Othus, PhD, Mikkael A Sekeres, MD, MS, Sucha Nand, MD, Guillermo Garcia-Manero, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD, PhD and Elihu H. Estey, MD

Comparable Outcomes of Patients Eligible versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies
Co-Authors: Abby Statler, MPH, MA, Megan Othus, PhD, Harry Erba, MD, PhD, Thomas Chauncey, MD, PhD, Jerald Radich, MD, Steven Coutre, MD, Anjali Advani, MD, Sucha Nand, MD, Farhad Ravandi, MD, Sudipto Mukherjee, MD, PhD, and Mikkael A. Sekeres, MD, MS

Diagnosis Patterns for Acute Myeloid Leukemia (AML) Compared to World Health Organization (WHO) 2008 Recommendations: Outcomes from the Prospective CONNECT® MDS/AML Disease Registry
Co-Authors: Tracy I. George, Daniel A. Pollyea, Medrdad Abedi, Rafael Bejar, Christopher R. Cogle, Guillermo Garcia-Manero, David Grinblatt, Rami Komrokji, Jaroslaw Maciejewski, Dennis Revicki,  Gail Roboz, Michael R. Savona, Bart Scott, Mikkael A. Sekeres, David P. Steensma, Michael A. Thompson, Al Fliss, Pavel Kiselev, Arlene Swern, Melissa Nifenecker, Pavel Kiselev, Harry Erba, Mary Sugrue, Kathryn Foucar

Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)
Co-Authors: Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Najla H Al Ali, Gail J. Roboz, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Jaime Fensterl, Guillermo Garcia-Manero, MD, Alan F List, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, M.D., M.S.

Advertising Policy

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Co-Authors: Rami S Komrokji, John Barnard, Amy Dezern, David P. Steensma, Gail Robotz, Guillermo Garcia-Manero Najla H Al Ali, Mikkael A. Sekeres

Ring sideroblasts and SF3B1 mutations in myelodysplastic syndromes (MDS): Are they two faces of the same coin? A study on behalf of the MDS Clinical Research Consortium (MDS CRC)
Co-Authors: Rami S Komrokji, John Barnard, David P. Steensma, Amy DeZern, Gail Roboz, Najla al ali, Jaime Fenstrel, Guillermo Garcia-Manero, Mikkael A. Sekeres

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes (MDS)
Co-Authors: Valeria Visconte, Bartlomiej Przychodzen, Steffan T. Nawrocki, Swapna Thota, Kevin R. Kelly, Bhumika J. Patel, Cassandra Hirsch, Hetty E. Carraway, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, Heesun J. Rogers, Jaroslaw P. Maciejewski, Jennifer S. Carew

Targeting Autophagy in Myelodysplastic Syndromes
Co-Authors: Valeria Visconte, Steffan T. Nawrocki, Bartlomiej Przychodzen, Kevin R. Kelly, Yin Mei, Yvonne Parker, Michael Clemente, John Barnard, Anjali S. Advani, Hetty E. Carraway, Mikkael A. Sekeres, Daniel J. Lindner, Heesun J. Rogers, Jaroslaw P. Maciejewski, Jennifer S. Carew

Pathogenic Relevance of Germ Line TET2 Alterations
Co-Authors: Cassandra M Hirsch, Aziz Nazha, MD, Kassy Kneen, Manja Meggendorfer, Bartlomiej P Przychodzen, Michael J. Clemente, MS,  Hetty E. Carraway, MD, Mikkael A. Sekeres, MD, MS, Torsten Haferlach MD, PhD, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD, PhD

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating agents in Myelodysplastic Syndromes
Co-Authors: Aziz Nazha, MD, Mikkael A. Sekeres, MD, MS, Rafael Bejar, MD, PhD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P Przychodzen, MSc, Matt Kalaycio, MD, Michael J. Clemente, M.S., Cassandra M. Hirsch, BSc, Benjamin L Ebert, MD, PhD, Jaroslaw P. Maciejewski

U2AF1 Mutations in S35 and Q157 Create Distinct Molecular and Clinical Contexts
Co-Authors: Vera Adema, PhD, Cassandra M. Hirsch, Bartlomiej P Przychodzen, Aziz Nazha, MD, Hideki Makishima, MD, PhD, Michael J. Clemente, MS, Hetty E. Carraway, MD, MBA, Mikkael A. Sekeres, MD, MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD, PhD

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating agents in Myelodysplastic Syndromes
Co-Authors: Aziz Nazha, Mikkael A. Sekeres, Rafael Bejar, John Barnard, Karam Al-Issa, Bartlomiej Przychodzen, Matt Kalaycio, Michael Clemente, Cassandra M. Hirsch, Benjamin Ebert, Jaroslaw P. Maciejewski

Subcutaneous low dose alemtuzumab: role as a salvage therapy in immune –mediated marrow failure conditions
Co-Authors: Swapna Thota, Srinivasa Sanikommu, Bhumika J Patel, Meena Sadaps, Cassandra Hirsch, Michael J. Clemente, Antonio M. Risitano, Alan Lichtin, Mikkael A. Sekeres, Jaroslaw Maciejewski

Germline Variants of RUNX-1 in Myeloid Malignancy
Co-Authors: Alek Nielsen, B.S., Sayer Al-Harbi, PhD, Cassandra Hirsch M.S., Michael Clemente M.S.,  Bartlomiej Przychodzen PhD, Mikkael A. Sekeres MD, MS, Yogen Saunthararajah MD, Hetty E. Carraway MD, MBA, and Jaroslaw P. Maciejewski, M.D., PhD

Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms
Co-Authors: Balasubramanian SK, Aly M, Bat T, Patel B, Przychodzen B, Hirsh C, Nazha A, Sekeres MA, Carraway H, Maciejewski JP

Clinical and biological implications of CUX1 mutations in myeloid neoplasms
Co-Authors: Aly M, N Hosano , B Przychodzen1, H Makishima , Y Nagata, C Hirsh, Sekeres MA, Maciejewski JP

Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage
Co-Authors: Bhumika Patel, MD; Caner Saygin, MD; Bartlomiej Przychodzen, MS; Cassandra Hirsch; Michael Clemente; Betty Hamilton, MD; Anjali S. Advani, MD; Aziz Nazha, MD; Sarah Ondrejka, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Hetty Carraway, MD, MBA; Jaroslaw Maciejewski, MD, PhD

Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms
Co-Authors: Cassandra M Hirsch, Aziz Nazha, MD, Kassy Kneen, Manja Meggendorfer, Bartlomiej P Przychodzen, Michael J. Clemente, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD, Mikkael A. Sekeres, MD, MS, Torsten Haferlach. MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion
Co-Authors: Vera Adema, PhD, Cassandra M. Hirsch, Bartlomiej P Przychodzen, Andrea Pellagatti, PhD, Jacqueline Boultwood, PhD, Aziz Nazha, MD, Hetty E. Carraway, MD, MBA, Francesc Sole, PhD, Mikkael A. Sekeres, MD, MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD, PhD

Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag
Co-Authors: Bhumika J. Patel MD, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Cassandra M. Hirsch, Caner Saygin MD, Marissa Varsalle, MD, Roy Souaid, MD, Valeria Visconte, PhD, Tomas Radivoyevitch PhD, Suresh Kumar Balasubramanian MD, Taha Bat MD, Swapna Thota, MD, Aziz Nazha, MD, Hetty E. Carraway, MD, MBA, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD

Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome
Co-Authors: Eiju Negoro, M.D., Ph.D., Michael Clemente, M.S., Naoko Hosono, M.D., Ph.D., Aziz Nazha, MD, Wenyi Shen, M.D., Yasunobu Nagata, M.D., Ph.D., Cassandra M. Hirsch, BSc, Bartlomiej P Przychodzen, MSc, Reda Z. Mahfouz, M.D., Ph.D., Teodora Kuzmanovic, BSc, Hideki Makishima, MD, PhD, FACP., Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, M.D., Ph.D.

Landscape of subclonal mutations in Myelodysplastic Syndromes (MDS) allows for a novel hierarchy of clonal advantage  by combining germline and somatic mutations
Co-Authors: Yasunobu Nagata, Hideki Makishima, Tomas Radivoyevitch, Cassandra M Hirsch, Bartlomiej Przychodzen, Teodora Kuzmanovic, Samuel Li, Kenichi Yoshida, Vera Adema, Eiju Negoro, Michael Clemente, Naoko Hosono, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Sudipto Mukherjee, Aziz Nazha, Francesc Sole, Hetty E. Carraway, Satoru Miyano, Thomas LaFramboise, Mikkael A. Sekeres, Seishi Ogawa, Jaroslaw P. Maciejewski

Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals
Co-Authors: Peter W Chomczynski, Michael J. Clemente, M.S., Srinivasa Reddy Sanikommu, MD, Alek d Nielsen, B.S., Cassandra M. Hirsch, BSc, Hanna Rajala, MD, Mikkael A. Sekeres, MD, MS, Hetty E. Carraway, MD, MBA, Satu Mustjoki, MD, PhD, Alan E. Lichtin, MD and Jaroslaw P Maciejewski, MD, PhD, FACP

PHF6 somatic mutations and their functional role in the pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Co-Authors: Bartlomiej Przychodzen, Dewen You, Hideki Makishima, Cassie Hirsch, Michael Clemente, Xiarom Gu, Aziz Nazha , Mikkael A. Sekeres, Jaroslaw Maciejewski

TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS)
Co-Authors: Karam Al-Issa, MD, Mikkael A. Sekeres, MD, MS, Alek d Nielsen, B.S., Babal Jha, Ph.D, Bartlomiej P Przychodzen, MSc, Mai Aly, Hetty E. Carraway, MD, MBA, Anjali S. Advani, MD, Bhumika Patel, MD, Michael J. Clemente, M.S., Sudipto Mukherjee, M.D., Ph.D., M.P.H., Aaron T. Gerds, MD, MS, Jaroslaw P Maciejewski, MD, PhD, FACP, Aziz Nazha, MD

Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia
Co-Authors: Alessandro Coppe, Emma Andersson, Andrea Binatti, Vanessa Gasparini, Sabrina Bortoluzzi, Michael Clemente, Marco Herling, Jaroslaw Maciejewski, Satu Mustjoki, Stefania Bortoluzzi

UTX Mutations in Myeloid Neoplasms
Co-Authors: Yasunobu Nagata, Tomas Radivoyevitch, Hideki Makishima, Cassandra M Hirsch, Bartlomiej Przychodzen, Teo Kuzmanovic, Eiju Negoro, Michael Clemente, Sudipto Mukherjee,Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski

Clonal Hierarchy of PIGA Mutant Cells Assessed by Next Generation Sequencing is More Complex than Previously Recognized in Paroxysmal Noctural Hemoglobinuria
Co-Authors: Michael J. Clemente, Bartlomiej Przychodzen, Cassandra Hirsch, Jaroslaw P. Maciejewski

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients
Co-Authors: Anthony Mato, MD, MSCE, Brian Hill, MD,PhD, Nicole Lamanna, MD, Paul Barr, MD, Chaitra Ujjani, MD, Danielle Brander, MD, Christina Howlett, Pharm D, BCOP, Alan Skarbnik, Md, Bruce Cheson,MD, Clive Zent, MD, Jeffrey Pu, MD, PhD, Pavel Kiselev, PhD, Spencer Henick Bachow, MD, Allison Winter, MD, Allan-Louie Cruz, MD, David Claxton, MD, Catherine Daniel, MD, krista Isaack, MD, Kaitlin Kennard, BSN, Colleen Timlin, PharmD, Molly Fanning, BS, Melissa Yancur, MD, Jakub Svoboda, MD, Stephen Schuster, MD and Chad Nabhan, MD, MBS, FACP

Toxicities and Outcomes of Ibrutinib-Treated patients in the United States: Large Retrospective Analysis of 621 Real world Patients
Co-Authors: Anthony Mato, MD, MSCE, Nicole Lamanna, MD,  Chaitra Ujjani, MD, Danielle Brander, MD, Brian Hill, MD,PhD,  Christina Howlett, Pharm D, BCOP, Alan Skarbnik, Md, Bruce Cheson,MD, Clive Zent, MD, Jeffrey Pu, MD, PhD, Pavel Kiselev, PhD, Spencer Henick Bachow, MD, Allison Winter, MD, Allan-Louie Cruz, MD, David Claxton, MD, Catherine Daniel, MD, Krista Isaack, MD, Kaitlin Kennard, BSN, Colleen Timlin, PharmD,Melissa Yancur, MD, Molly Fanning, MD, Lauren Strelec, BA, Daniel Landsburg, MD, Sunita Dwivedy Nasat, MD, Stephen Schuster, MD, David Porter, MD Chad Nabhan, MD, MBS, FACP and Paul Barr, MD

IPI, Comorbidity Index, Hospitalization for Treatment-Related Adverse Events Are Predictors for Outcome in Elderly Diffuse Large B Cell Lymphoma Patients
Co-Authors: Caner Saygin, MD, Xuefei Jia, MS, Brian T. Hill, MD, PhD, Robert M. Dean, MD, Bhumika Patel, MD, Brad Pohlman, MD, Mitchell R. Smith and Deepa Jagadeesh, MD, MPH

Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study
Co-Authors: Andrew M Evens, DO, MSc, FACP, Monika Pilichowska, MD, Stefania Pittaluga, MD, PhD, Judith Ferry, MD, Jessica Hemminger, MD, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, MD, Jeremy S. Abramson, MD, Francisco J. Hernandez-Ilizaliturri, MD, Izidore Lossos, MD, Oliver W Press, MD, PhD, Timothy S. Fenske, MD, Jonathan Friedberg, MD, Julie M Vose, MD, Kristie A. Blum, MD, Deepa Jagadeesh, Gaurav Gupta, MD, PhD, Randy D Gascoyne, MD, Elaine Jaffe, MD

An Update on Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-cell Receptor Pathway Signaling
Co-Authors: Jeff P Sharman, Andrei R Shustov, Mitchell R Smith,  Thomas E Boyd,  Christopher T Hagenstad, Kathryn S. Kolibaba, Esteban Abella-Dominicis, Danjie Zhang, Siddhartha Mitra, Christopher A. Yasenchak, Farrukh T. Awan

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety
Co-Authors: David S. Siegel, Gary J. Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J. Reu, Eshan Malek, Jorge Mouro, Weiyuan Chung, Shankar Srinivasan, Max Qian,Syed Rizvi, Anjan Thakurta, Nizar J. Bahlis

Response-Adapted Therapy for Newly Diagnosed Myeloma
Co-Authors: Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD, RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD, FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD and Mitchell R. Smith

Inhibition of Cyclin-Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells
Co-Authors: Xiaoxian Zhao, Juraj Bodo, Ruoying Chen, Lisa Durkin, Andrew J. Souers, Darren C. Phillips and Eric D. Hsi

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells
Co-Authors: Xiaoxian Zhao, Ph.D., Juraj Bodo, PhD, Ruoying Chen, PhD, Lisa Durkin, Andrew J. Souers, PhD, Darren C. Phillips, PhD, Eric D. Hsi, MD

Early Relapse of Follicular Lymphoma After Rituximab-Based Biologic Doublet Upfront Therapy Is Associated With Increased Risk of Death: A Combined Analysis From CALGB/Alliance Studies 50402, 50701 and 50803
Co-Authors: Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin-Ho Jung, Bruce Cheson, Myron Czuczman, Barbara Grant, Peter Martin, Eric Hsi, Heiko Schroder, Nancy Bartlett, John P. Leonard, Kristie A. Blum